Gene therapy in Parkinson's disease: targeting the endplasmic reticulum proteostasis network  

作　　者：Valentina Castillo Gabriela Mercado Claudio Hetz 

机构地区：[1]Biomedical Neuroscience Institute, Faculty of Medicine,University of Chile [2]Program of Cellular and Molecular Biology, Center for Molecular Studies of the Cell, Institute of Biomedical Sciences,University of Chile [3]Department of Immunology and Infectious Diseases, Harvard School of Public Health

出　　处：《Neural Regeneration Research》2015年第7期1053-1054,共2页中国神经再生研究（英文版）

基　　金：supported by FONDECYT-11140738 (G.M.).;Michael J. Fox Foundation for Parkinson Research, Ring Initiative ACT1109;FONDEF D11I1007 (C.H.). We also thank, FONDECYT-1140549;Millennium Institute P09-015-F, COPEC-UC, and Frick Foundation (C.H.). V.C. is supported by CONICYT fellowship

摘　　要：Parkinson’s disease（PD）is the second most common neurodegenerative disease affecting 1%of the population over 60 years of age.The progressive degeneration of dopaminergic neurons at the substantia nigra pars compacta（SNpc）results in a severe and gradual depletion of dopamine content in the striatum,a phenomena that is responsible for the characteristic motor symptoms of this disease.Parkinson’s disease（PD）is the second most common neurodegenerative disease affecting 1%of the population over 60 years of age.The progressive degeneration of dopaminergic neurons at the substantia nigra pars compacta（SNpc）results in a severe and gradual depletion of dopamine content in the striatum,a phenomena that is responsible for the characteristic motor symptoms of this disease.

关 键 词：gene Gene therapy in Parkinson’s disease targeting the endplasmic reticulum proteostasis network 

分 类 号：R742.5[医药卫生—神经病学与精神病学]